Plasma long-chain omega-3 fatty acids and atrophy of the medial temporal lobe. by Samieri, Cécilia et al.
HAL Id: hal-01164730
https://hal.archives-ouvertes.fr/hal-01164730
Submitted on 17 Jun 2015
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution - NonCommercial| 4.0 International
License
Plasma long-chain omega-3 fatty acids and atrophy of
the medial temporal lobe.
Cécilia Samieri, Pauline Maillard, Fabrice Crivello, Cécile Proust-Lima,
Evelyne Peuchant, Catherine Helmer, Helene Amieva, Michele Allard,
Jean-Francois Dartigues, Stephen C Cunnane, et al.
To cite this version:
Cécilia Samieri, Pauline Maillard, Fabrice Crivello, Cécile Proust-Lima, Evelyne Peuchant, et al..
Plasma long-chain omega-3 fatty acids and atrophy of the medial temporal lobe.. Neurology, American
Academy of Neurology, 2012, 79, pp.642-50. ￿hal-01164730￿
Plasma long-chain omega-3 fatty acids and
atrophy of the medial temporal lobe
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ABSTRACT
Objective: The long-chain -3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) are potential candidates for interventions to delay Alzheimer disease (AD), but evidence
from clinical studies is mixed. We aimed at determining whether plasma levels of EPA or DHA
predict atrophy of medial temporal lobe (MTL) gray matter regions in older subjects.
Methods: A total of 281 community dwellers from the Three-City Study, aged 65 years or older,
had plasma fatty acid measurements at baseline and underwent MRI examinations at baseline
and at 4 years. We studied the association between plasma EPA and DHA and MTL gray matter
volume change at 4 years.
Results: Higher plasma EPA, but not DHA, was associated with lower gray matter atrophy of the
right hippocampal/parahippocampal area and of the right amygdala (p  0.05, familywise error cor-
rected). Based on a mean right amygdala volume loss of 6.0 mm3/y (0.6%), a 1 SD higher plasma EPA
(0.64% of total plasma fatty acids) at baseline was related to a 1.3 mm3 smaller gray matter loss
per year in the right amygdala. Higher atrophy of the right amygdala was associated with greater
4-year decline in semantic memory performances and more depressive symptoms.
Conclusion: The amygdala, which develops neuropathology in the early stage of AD and is involved in
the pathogenesis of depression, may be an important brain structure involved in the association be-
tween EPA and cognitive decline and depressive symptoms. Neurology® 2012;79:642–650
GLOSSARY
3C  Three-City; AD  Alzheimer disease; CES-D  Center for Epidemiologic Studies–Depression; DHA  docosahexaenoic
acid; DSM-IV  Diagnostic and Statistical Manual of Mental Disorders, 4th edition; EPA  eicosapentaenoic acid; GM  gray
matter; IST  Isaacs Set Test; MMSE  Mini-Mental State Examination; MTL  medial temporal lobe; n-3 PUFA  -3
polyunsaturated fatty acids; n-6 PUFA  -6 polyunsaturated fatty acids; TIV  total intracranial volume; WM  white matter.
The long-chain -3 polyunsaturated fatty acids (n-3 PUFA) eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) in fish are promising candidates for prevention of sporadic Alz-
heimer disease (AD).1,2 DHA is a major component of neuron membranes where it exerts a
structural and functional role. EPA is present in the brain in much lower amounts than DHA
but, like DHA, may also have neuroprotective properties through anti-inflammatory, antioxi-
dant, and energy metabolism pathways.2
Several prospective epidemiologic studies directly link higher fish consumption, or higher
blood status of EPA or DHA, to lower risk of dementia, AD, or cognitive decline.1,2 However,
to date, most clinical trials using fish oil or DHA supplements have been inconclusive.2–5 More
evidence for a specific neurotherapeutic target of EPA and DHA is therefore needed, based
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on validated biomarkers of AD, such as at-
rophy of medial temporal lobe (MTL)
structures. In older subjects, lower red
blood cell EPADHA levels were recently
shown to correlate with smaller brain vol-
umes.6 However, to our knowledge, the as-
sociation between plasma EPA and DHA
and brain atrophy has not been explored us-
ing a longitudinal design.
The primary objective of this population-
based MRI study was to examine whether
plasma EPA or DHA were associated with
whole brain and MTL-specific gray matter
(GM) volume change over 4 years. Secondly,
we sought to determine whether GM volume
change in the MTL regions involved in such
relationship was associated with a decline of
cognitive performance or an increase of de-
pressive symptoms during follow-up.
METHODS Study population. The present study is based
on the Bordeaux sample of the Three-City (3C) Study, a pro-
spective cohort study of vascular risk factors for dementia which
started in 1999–2000 and included 9,294 noninstitutionalized
community dwellers aged 65 years in Bordeaux (n  2,104),
Dijon (n  4,931), and Montpellier (n  2,259), France. De-
tails of the study were described previously.7 Baseline data collec-
tion included sociodemographic and lifestyle characteristics,
symptoms and complaints, main chronic conditions, neuropsy-
chological testing, physical examination, and blood sampling.
Four follow-up examinations were performed 2, 4, 7, and 10
years after baseline. The present study is based on the first 4 years
of follow-up.
In Bordeaux, plasma fatty acids were measured at baseline in
1,419 participants (figure e-1 on the Neurology® Web site at
www.neurology.org). Among them, 504 individuals also underwent
a brain MRI examination. At 4 years, 315 participants underwent a
second MRI examination. We excluded 30 participants with unus-
able scans and 4 with missing data for main covariates, leaving 281
participants available for the present study.
Standard protocol approvals, registrations, and patient
consents. The protocol of the 3C study has been approved by
the Consultative Committee for the Protection of Persons par-
ticipating in Biomedical Research of the Kremlin-Bicêtre Uni-
versity Hospital (Paris). All participants gave their written
informed consent.
MRI data. MRI acquisition. The MRI acquisition was per-
formed on a 1.5-T Magnetom (Siemens, Erlangen, Germany). A
3D, high-resolution T1-weighted brain image was acquired us-
ing a 3D inversion recovery fast spoiled-gradient echo sequence.
T2- and proton density–weighted brain volumes were acquired
during the same sequence using a 2D dual spin echo sequence
with 2 echo times (e-Methods).
MRI processing. Using the multi-spectral segmentation
scheme implemented in SPM8 (Statistical Parametric Mapping,
release 8),8 baseline T1 and T2 images were first segmented into
GM, white matter (WM), and CSF images and then spatially
normalized using a 3C template (e-Methods). Probability maps
were smoothed using a 12-mm full width at half-maximum iso-
tropic Gaussian kernel.
Whole brain and MTL volumes estimation. A so-called
modulation8 was applied to the resulting individual GM, WM,
and CSF probability maps to preserve the subject’s original tissue
quantity after its transfer to the reference space. Baseline and
4-year GM, WM, and CSF volumes were computed as the inte-
gral of the voxel intensities in the corresponding modulated tis-
sue image, and total intracranial volume (TIV) was defined as
their sum. Baseline and 4-year MTL volumes were automatically
computed within the MTL limits derived from a model of mac-
roscopic neuroanatomic parcellation.9,10 Three MTL structures
were selected: 1) the hippocampal region consisting of the den-
tate gyrus, the uncus, and the hippocampus; 2) the parahip-
pocampal region consisting of the parahippocampal gyrus; and
3) the parahippocampal uncus, both including entorhinal and
perirhinal cortices, and the amygdala.
The individual annual rates of GM volume change were defined
as the difference between the 4-year and baseline GM volumes di-
vided by the time between the 2 MRI examinations. Probability
maps of annual GM change (/y GM map) were calculated as the
difference between 4-year and baseline GM probability maps di-
vided by the time between the 2 MRI examinations.
Clinical data. Cognitive assessment. The psychologists ad-
ministered a battery of neuropsychological tests at baseline and
at each follow-up examination. In the present study, we were
interested in the Mini-Mental State Examination (MMSE),11 an
index of global cognitive performance (range 0–30), and the
Isaacs Set Test (IST),12 which assesses semantic verbal fluency
and begins to decline very early in the prodromal phase of AD.13
For the IST, participants have to generate a list of words belong-
ing to a specific semantic category in 15 seconds. Four semantic
categories are successively used (cities, fruits, animals, and colors)
(range 0–53).
Diagnosis of dementia was based on a 3-step procedure.7 All
potential incident cases of dementia were reviewed by an inde-
pendent committee of neurologists to obtain a consensus on the
diagnosis and etiology according to the criteria of the DSM-IV.14
Assessment of depressive symptoms. Depressive symptoms
were recorded by trained psychologists at baseline and at the
2-year and 4-year visits with the validated Center for Epidemio-
logic Studies–Depression (CES-D) scale.15,16 Scores range from 0
to 60 according to the frequency of the depressive symptoms
during the previous week. High depressive symptoms were de-
fined as a CES-D score of 17 in men and 23 in women, as
validated in a French population.17
Plasma fatty acids. Plasma fatty acid composition was de-
termined from fasting blood samples collected at baseline, as
previously detailed18 (e-Methods). For this study, the focus was
on plasma EPA and DHA proportions (in percentage of total
fatty acids), transformed into Z scores. In supplementary analy-
ses, we also considered total n-3 PUFA (as the sum of -linolenic
acid  docosapentaenoic acid  EPA  DHA), total -6 poly-
unsaturated fatty acids (n-6 PUFA) (as the sum of linoleic acid 
-linolenic acid  arachidonic acid), as well as total PUFA (as
the sum of n-3 and n-6 PUFA).
Other variables. Sociodemographic variables included age,
sex, and education. APOE4 allele carrier status was considered
dichotomously (at least 1 4 allele vs no 4 allele). Vascular risk
factors at baseline included smoking, history of cardiovascular or
cerebrovascular disease, hypertension (if systolic blood pressure
140 mmHg or diastolic blood pressure 90 mm Hg, or anti-
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hypertensive medication), hypercholesterolemia (if plasma total
cholesterol 6.20 mmol/L, or cholesterol-lowering medication),
diabetes (if fasting glycemia 7.0 mmol/L, or antidiabetic med-
ication), body mass index (body weight/height2 [kg/m2]), tri-
glyceridemia, and usual alcohol consumption.
In Bordeaux, a detailed food frequency questionnaire was
administered at the 2-year and 4-year visits; the stability of fish
consumption between these 2 periods was assessed within each
quartile of baseline plasma EPA and DHA (e-Methods).
Statistical analyses. Statistical analyses at the voxel level:
VBM. Whether plasma long-chain n-3 PUFA was associated
with the probability of GM was tested in each voxel. Using the
smoothed normalized GM maps, multiple linear regressions
were performed in the MTL to assess associations between base-
line EPA or DHA plasma proportion and annual GM change,
adjusting for baseline age, gender, education, and APOE4 status.
The threshold was set at p  0.05 (familywise error–corrected
for multiple comparisons). In additional models, we secondarily
considered total n-3, total n-6 PUFA, as well as total PUFA.
Statistical analyses at the global level. Individual estima-
tions of GM volumes in each MTL structure of interest were
used to investigate, when significant in VBM, 1) associations
between EPA or DHA or total PUFA and annual change in GM,
taking into account a broader set of adjusting variables, and 2)
whether GM volume change in the regions involved was associated
with a decline of cognitive performance or an increase in depressive
symptoms. SAS statistical software (release 9.1, SAS institute Inc,
Cary, NC) and lcmm R package19 were used, and statistical tests
were computed at the   0.05 level of significance.
Association between plasma n-3 PUFA and MRI data.
For each MTL structure, GM volume change was described us-
ing linear mixed models.20 The mean trajectory of GM change
was modeled as a linear trend with the baseline mean GM vol-
ume (intercept) and the annual change in GM volume (slope)
allowed varying with the PUFA of interest. Interindividual vari-
ability was accounted for through correlated subject-specific ran-
dom intercept and slope. Three different adjusted models were
constructed which respectively included as covariates: 1) TIV,
age, gender, education, and APOE4 status (model 1), 2) and
depressive symptoms and vascular risk factors (model 2), 3) and
whole brain GM volume change (model 3).
Association between MRI data and clinical data. For
each MTL structure significantly associated with n-3 PUFA, we
further examined whether annual GM volume change (/y GM
volume) was associated with the evolution of cognitive perfor-
mances and depressive symptoms during the same period, using
latent process mixed models that, compared to standard linear
mixed models, correct for the curvilinearity of the tests/scales.19,21
Change of the latent process underlying MMSE, IST, and
CES-D scores was modeled as an individual-specific linear trend
(with random intercept and slope). Association with /y GM
volume was assessed on the slope only, while associations with
other covariates (baseline GM volume of the MTL structure,
age, gender, education, and TIV) were evaluated both on the
intercept and the slope of the underlying latent process.
RESULTS Participants were 72.3 years old, 42.2%
were male, and mean MMSE score was 27.9 (table
1). Baseline plasma EPA and DHA were associated
with frequency of fish consumption at 2 and 4 years,
and within each quartile of plasma EPA, mean fre-
quency of fish consumption remained stable during
follow-up (e-Results and table e-1). Fish consump-
tion remained stable over the 4 years in the extreme
quartiles of plasma DHA, and slightly increased in
the intermediate quartiles. The subjects who agreed
to have MRI were healthier than those who did not,
including having better nutritional status (e-Results).
Association between plasma long-chain n-3 PUFA and
MRI data. The mean rate of GM atrophy from base-
line was 0.2%/y in the whole brain. In the MTL, it
ranged from 0.5%/y for the left amygdala to
1.0%/y for the left hippocampus (table 2).
On a voxel-by-voxel basis, higher baseline plasma
EPA was significantly associated with less GM atro-
phy in a region of which 53% was the right
amygdala, 41% was the right parahippocampus, and
Table 1 Baseline characteristics of the
participants: The Bordeaux sample
of the Three-City Study (n  281)
Characteristics Values
Age, y, mean (SD) 72.3 (3.8)
Male, n (%) 119 (42.3)
Educational level, n (%)
None or primary 67 (23.8)
Secondary 73 (26.0)
High school 70 (24.9)
University 71 (25.3)
APOE4,a n (%) 64 (22.8)
BMI, mean (SD) 26.2 (3.8)
Smoking, n (%)
Never 176 (62.6)
Former 91 (32.4)
Current 14 (5.0)
No. of glasses of alcoholic
beverages per week, mean (SD)
14.6 (16.7)
History of cardiovascular
disease, n (%)
29 (10.3)
Diabetes,b n (%) 23 (8.2)
Hypercholesterolemia,c n (%) 166 (59.1)
Hypertension, n (%) 168 (59.8)
Triglycerides,c mmol/L, mean (SD) 1.2 (0.6)
CES-D score, median (Q1–Q3) 4 (1–8)
MMSE score, mean (SD) 27.9 (1.8)
EPA, % total fatty acids, mean (SD)
(range)
1.1 (0.6) (0.3–5.0)
DHA, % total fatty acids, mean (SD)
(range)
2.4 (0.8) (0.6–5.7)
Abbreviations: BMI  body mass index; CES-D  Center for
Epidemiologic Studies–Depression scale; DHA  docosa-
hexaenoic acid; EPA  eicosapentaenoic acid; MMSE 
Mini-Mental State Examination.
a APOE4 carriers (at least one 4 allele) were noted as
APOE4.
b Data missing for 3 participants.
c Data missing for 1 participant.
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6% was the right hippocampus (figure 1). More than
45% of the whole right amygdala, but 10% of the
whole right hippocampal/parahippocampal area,
were included in this cluster. In contrast to plasma
EPA, plasma DHA, as well as plasma total PUFA,
total n-3, and total n-6 PUFA, were not significantly
associated with GM volume change (data not
shown). When plasma EPA and DHA were intro-
duced together in a same model, higher EPA but not
DHA was associated with less GM atrophy in the
aforementioned brain region (data not shown).
At the global level, higher plasma EPA was signifi-
cantly associated with less GM atrophy of the right
amygdala (whole structure) over 4 years, but not with
the 4-year change in the volume of the other MTL re-
gions (table 3) or of the whole brain (table e-2). This
association remained significant after adjustment for
vascular risk factors, depressive symptoms (model 2),
Table 2 Mean baseline GM volume and rate of change of GM in the whole brain and in MTL regions
of interest
Whole brain
Baseline GM volume (cm3),
mean (SD)
GM volume change (cm3/y),
mean (SD)
GM rate of change from baseline (%/y),
mean (SD)
520.6 (50.6) 0.8 (1.4) 0.2 (0.3)
Regions of interest Baseline GM volume (mm3) GM volume change (mm3/y) GM rate of change from baseline (%/y)
Left hippocampus 3,979.0 (433.7) 40.8 (31.0) 1.0 (0.8)
Right hippocampus 3,605.2 (414.3) 32.4 (26.9) 0.9 (0.8)
Left parahippocampal
regiona
3,578.6 (361.9) 20.4 (26.6) 0.6 (0.7)
Right parahippocampal
regiona
4,547.2 (483.5) 26.0 (34.5) 0.6 (0.8)
Left amygdala 940.4 (92.0) 4.2 (8.5) 0.5 (0.9)
Right amygdala 977.3 (102.1) 6.0 (8.4) 0.6 (0.9)
Abbreviations: GM  gray matter; MTL  medial temporal lobe.
a Consisted of the parahippocampal gyrus and the parahippocampal uncus, both including entorhinal and perirhinal
cortices.
Figure 1 Specific area of lower gray matter atrophy over 4 years within the medial temporal lobe with each
1 SD increase of plasma eicosapentaenoic acid, after adjustment for age, gender, education,
APOE4 carrier status, and correcting for total intracranial volume (n  281)
Student t map is superimposed onto the gray matter probability map, displayed at p  0.05 familywise error corrected for
multiple comparisons. The x, y, and z coordinates (mm) give the slice location in stereotactic space. The region of interest
included the hippocampal region consisting of the dentate gyrus, the uncus, and the hippocampus, the parahippocampal
region consisting of the parahippocampal gyrus and the parahippocampal uncus, both including entorhinal and perirhinal
cortices, and the amygdala.
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and whole brain GM volume change (model 3). The
results were virtually unchanged after excluding the 13
stroke cases (9 prevalent at baseline, 4 incident) or the 4
dementia cases (1 prevalent, 3 incident).
Association between annual GM change in the
amygdala and clinical data. Greater 4-year atrophy of
the left amygdala was significantly associated with
greater MMSE score decline (figure 2A). Greater left
and right amygdala atrophy was associated with
greater IST decline (figure 2, C and D). Finally,
greater atrophy of the right amygdala was associated
with increased CES-D scores over time (figure 2F).
In this sample, higher plasma EPA or DHA were not
significantly associated with change in MMSE, IST,
or CES-D scores.
DISCUSSION In the present study, higher baseline
plasma EPA but not DHA was associated with less
GM atrophy over 4 years of both the right amygdala
and part of the right hippocampal/parahippocampal
area. At the global level, only the association between
plasma EPA and GM atrophy of the right amygdala
was statistically significant. After adjustment for po-
tential confounders, and based on a mean right
amygdala volume loss of 6.0 mm3/y (0.6%), a 1
SD higher plasma EPA (0.64% of total plasma
fatty acids) at baseline was related to a 1.3 mm3
smaller GM loss per year in the right amygdala, inde-
pendently of the degree of whole brain GM atrophy.
Furthermore, more atrophy of the right amygdala
was associated with higher decline in semantic mem-
ory performance, and, specifically, with increased
symptoms of depression during the 4-year follow-up.
In our study, neither plasma EPA nor DHA were
significantly associated with change in whole brain
GM volume. This result is consistent with the Car-
diovascular Health Study and the Oregon Brain Ag-
ing Study, both of which did not find any significant
relation of fish consumption or marine -3 nutrient
biomarker pattern, respectively, to whole brain vol-
umes.22,23 Conversely, the Framingham Study re-
cently reported an association between lower red
blood cell DHA and smaller whole brain volume.6
Our results are, however, very similar to a previous
Table 3 Multivariate associationsa between baseline plasma EPA and GM volume change (mm3/y) over 4
years in MTL regions of interest
Model 1 (n  281) Model 2 (n  275) Model 3 (n  275)
 (SE) p  (SE) p  (SE) p
Left hippocampus
EPA 12.0 (14.8) 0.42 9.7 (15.2) 0.52 9.8 (15.2) 0.52
EPA  time 0.1 (1.9) 0.96 0.4 (2.0) 0.82 0.1 (1.9) 0.95
Right hippocampus
EPA 6.2 (15.7) 0.69 12.6 (15.8) 0.42 12.6 (15.8) 0.43
EPA  time 1.7 (1.7) 0.31 1.9 (1.7) 0.26 1.7 (1.7) 0.31
Left parahippocampal regionb
EPA 7.8 (13.2) 0.55 8.4 (13.6) 0.53 8.5 (13.6) 0.53
EPA  time 0.1 (1.6) 0.94 0.3 (1.7) 0.85 0.1 (1.6) 0.97
Right parahippocampal regionb
EPA 3.9 (18.1) 0.83 16.6 (18.4) 0.37 16.6 (18.4) 0.37
EPA  time 0.9 (2.2) 0.66 1.0 (2.2) 0.65 0.6 (2.2) 0.78
Left amygdala
EPA 4.3 (3.5) 0.21 4.8 (3.6) 0.18 4.8 (3.6) 0.18
EPA  time 0.5 (0.5) 0.38 0.7 (0.5) 0.17 0.6 (0.5) 0.22
Right amygdala
EPA 3.7 (3.9) 0.34 4.7 (4.0) 0.25 4.7 (4.0) 0.25
EPA  time 1.2 (0.5) 0.02 1.4 (0.5) 0.01 1.3 (0.5) 0.01
Abbreviations: EPA  eicosapentaenoic acid; GM  gray matter; MTL  medial temporal lobe.
a Estimated using separate linear mixed models.  coefficients are expressed for 1 SD increase of plasma proportion of
total fatty acids. Model 1: adjusted for baseline total intracranial volume, age, education, gender, APOE4 carrier status, and
their interactions with time. Model 2: Model 1  depressive symptoms, body mass index, tobacco use, alcohol consumption,
history of cardiovascular and cerebrovascular disease, hypertension, hypercholesterolemia, diabetes, triglyceridemia, and
their interactions with time. Model 3: Model 2  whole brain GM volume change  time.
b Consisted of the parahippocampal gyrus and the parahippocampal uncus, both including entorhinal and perirhinal
cortices.
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Figure 2 Evolution of predicted scores on the MMSE, the IST, and the CES-D scale over 4 years as a
function of annual GM volume change of the left and right amygdala (n  281)
Latent process mixed models were used to describe the repeated measures of individual scores on the Mini-Mental State Exam-
ination (MMSE), the Issacs Set Test (IST), and the Center for Epidemiologic Studies-Depression (CES-D) scale function of time,
baseline amygdala gray matter (GM) volume, baseline amygdala GM volume  time, /y amygdala GM volume  time, age, age 
time, gender, gender  time, education, education  time, APOE4, APOE4  time, total intracranial volume (TIV), TIV  time. /y
GM volume refers to annual GM change in the amygdala. The left and the right amygdala were included in separate models. The
regressions were run in the scale of the latent process underlying the individual scores, and predicted scores were computed in
the scale of each psychometric test. Predicted mean evolution of MMSE, IST, and CES-D scores were represented for a man, 65
years old, low level of education (no or primary), non-APOE4 carrier, mean total intracranial volume (1,205 mm3) and mean
baseline GM volume of the amygdala (respectively: left amygdala, 940.4 mm3 and right amygdala: 977.3 mm3). Panels A and B
refer to the evolution of predicted MMSE score as a function of GM volume change of the left and right amygdala, respectively.
Panels C and D refer to the evolution of predicted IST score as a function of GM volume change of the left and right amygdala,
respectively. Panels E and F refer to the evolution of predicted CES-D score as a function of GM volume change of the left and
right amygdala, respectively.
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study in healthy adults, in which higher EPA and DHA
intake was associated with greater GM volume in the
subgenual anterior cingulate cortex, the right hip-
pocampus, and the right amygdala.24 Our longitudinal
study strengthens this cross-sectional result, suggesting
that in older subjects, higher EPA intake may be associ-
ated with lower GM loss in the right amygdala.
These results corroborate our previous findings
that EPA specifically (and not DHA, total n-3, or
total n-6 PUFA) is associated with slower cognitive
decline25 and dementia risk,18 and also with lower
depressive symptoms26 according to antidepressant
effects documented in randomized controlled tri-
als.27,28 Indeed, within the MTL, the rate of atrophy
not only of the hippocampus, but also of adjacent
structures such as the entorhinal cortex29 and the
amygdala,30 is predictive of progression to dementia
and AD, because these regions develop neuropathol-
ogy in the early stage of AD.31 Although left MTL
atrophy seems to be the most consistent brain bio-
marker predicting conversion from MCI to AD,32
atrophy of the right MTL, including the amygdala, is
also reported and may even be involved in earlier AD
stages, thus enabling differentiation of normal sub-
jects from subjects with MCI.33 Hence, in the ADNI
cohort, atrophy of some right but not left MTL
structures predicted subsequent decline in memory
in cognitively unimpaired older subjects.34
Accordingly, we found that higher decline in
global cognition was related to atrophy of the
amygdala on the left side only, while atrophy of the
right amygdala was related to decline in IST, a test
exhibiting very early decline in prodromal AD.13
Therefore, the specific association found between
EPA and the right MTL, also reported in a previous
study in healthy adults,24 suggests that EPA may ex-
ert beneficial properties in early stages of dementia,
which we were able to capture in our minimally cog-
nitively impaired sample.
In addition, MTL atrophy may occur as a conse-
quence of recurrent major depression. The amygdala,
which is the core structure of the limbic emotion-
processing circuit, plays a key role in the regulation
of mood and in the memory of emotional stimuli.35
Amygdala volume is significantly decreased in un-
medicated depressed patients but increases after
medication, supporting the neurotrophic hypothesis
of antidepressant action.36 The reactivity of the right
amygdala seems specifically altered in depression37
and may normalize with the use of selective serotonin
reuptake inhibitors.38 Accordingly, more symptoms
of depression were specifically related to atrophy of
the amygdala in the right hemisphere in our study.
In our study, higher plasma EPA levels had a fa-
vorable association with right medial temporal struc-
tures. EPA could exert neuroprotective effects
through anti-inflammatory, neuroendocrine, or
neurogenesis-related pathways (e-Discussion). Nev-
ertheless, interpreting our results requires caution: 1)
Probably because of limited power, we were not able
to repeat the association between plasma EPA and
clinical outcomes that we previously reported, and
we could thus not test the hypothesis of a possible
mediation by declining amygdala volume of such as-
sociation. 2) Reasons for the relative specificity of
relationship with EPA vs DHA remain speculative
(e-Discussion). The main strengths of the present
study include the 1) longitudinal MRI assessment of
brain volume, 2) large population-based sample, 3)
use of plasma fatty acid profiles to assess n-3 PUFA
status, and 4) adjustment for many potential con-
founding variables, including vascular risk factors.
Among potential limitations, plasma long-chain n-3
PUFA may reflect shorter-term dietary intake than
do n-3 PUFA measured in erythrocyte membranes.
However, stronger correlations have generally been
reported between dietary long-chain PUFA and the
proportion of long-chain PUFA in total plasma.39
Moreover, participants of this study who underwent
MRI were probably healthier than those who did
not, which may have biased cross-sectional associa-
tions, but this is less likely to have affected the longi-
tudinal assessments.40 We cannot dismiss the
possibility that drop-out between the 2 MRI exami-
nations may have generated bias in association mea-
sures; however, if present, it is more likely to have
occurred toward an underestimation of associations,
because we may have lost participants with worst nu-
tritional status (thus lower n-3 PUFA) and higher
brain atrophy. Finally, nonparticipation may hamper
the external validity of the study, whose findings
should not be generalized to the whole elderly popu-
lation but only to those similar to the sample ana-
lyzed here.
Our finding of a relationship between plasma
EPA and GM volume loss in the amygdala suggests
that future clinical trials with EPA supplements
could specifically target the volume of amygdala as an
outcome measure.
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tor Segalen Bordeaux 2 University. The Fondation pour la Recherche Médi-
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